Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1187 participants.
Also called NCT01325935
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,187 participants
- Sponsor
- Registry
-
NCT01325935
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01325935. Non-randomized; no masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2013-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
- Acronym
- OPERA
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Associations for Establishment of Evidence in Interventions
- Collaborator
- Medtronic
Record details
- Record id
cardio:ct-nct01325935- Content hash
103124797d116dc712f02261ced0aa9c2659f32838e72d133c7f27770256af07